Kornimate/medical-research-clean huggingface dataset:
interest of hypnosis on pain management during a guided echo infiltration of the hand

Conditions: Hand Injuries

Summary: ultrasound-guided infiltration is a common procedure and is known to be locally painful. this care-induced pain leads to strong apprehension in patients who need to benefit from this procedure. the practice of hypnosis to improve the patient's comfort during a treatment has appeared progressively in hospital departments. among the various existing conversational hypnosis techniques, there is the "magic glove" technique. this is the technique that will be used in this study. the investigators wish to evaluate the interest of hypnosis on the pain felt by the patient when performing an echo-guided infiltration of the hand, one of the most painful extremities during infiltrations.


Eligibility criteria:
inclusion criteria: * patient with an indication of a first hand infiltration under ultrasound examination * major patient * patient with capacity to understand the protocol and has given oral consent to participate in the research, * patient with social security coverage. exclusion criteria: * patient having preventively applied a pain patch to the area to be infiltrated * contraindication to infiltrations ( imbalanced diabetes, imbalanced,hypertension, ongoing infections). * hearing impaired patient * patient under guardianship/curtel * minor * pregnant woman * patient participating in another intervention research protocol * patient unable to follow the protocol as judged by the investigator.
implementation of a personalised health plan (php) on patient quality of life score at 2-year follow-up

Conditions: Elderly, Frail

Summary: "healthy ageing" is not limited to the absence of disease, but implies the "development and maintenance of the functional skills that enable the elderly to enjoy a state of well-being": (for example : the ability to walk, go out, engage in leisure activities, memorize...) it is interesting to study whether the implementation of a personal health plan (php) in a multiprofessional health home improves the quality of life of frail elderly people.

"healthy ageing" is not limited to the absence of disease, but implies the "development and maintenance of the functional skills that enable the elderly to enjoy a state of well-being": (for example : the ability to walk, go out, engage in leisure activities, memorize...) between "good health" and "dependence", there is a precarious, reversible state of transition known as frailty. there are several simple tools for identifying frailty, such as the gfst (gerontopole frailty screening tool). the gerontopole frailty screening tool and the fatigue, resistance, ambulation, illness, loss of weight questionnaire have proved more sensitive. the gold standard for diagnosing and assessing frailty is a comprehensive geriatric assessment based on the multidimensional model of the standardized geriatric assessment (sga). its aim is to identify all the medical, functional, psychological and social problems that may affect a frail elderly patient, in order to set up a long-term follow-up project, taking into account the patient's needs. it is interesting to study whether the implementation of a personal health plan in a multiprofessional health home improves the quality of life of frail elderly people.

Eligibility criteria:
inclusion criteria: * patient ≥ 70 years * autonomous patient (adl ≥ 5) * patient identified as frail according to the gérontopôle de toulouse gfst grid * patient whose primary care physician is in the msps of charleval or romilly sur andelle for the intervention group, and in the msps of gaillon and pont de l'arche for the control group. * patient living at home or in an rpa * understanding of the french language * patient having read and understood the information letter and signed the consent form * affiliation with a social security scheme exclusion criteria: * hospital geriatric follow-up * geriatric assessment already carried out * person deprived of liberty by an administrative or judicial decision, or placed under court protection / sub-guardianship or curatorship * history of illness or psychological or sensory abnormality likely to prevent the subject from fully understanding the conditions required for participation in the protocol, or from giving informed consent.

Keywords: identifying
experiences with hdr-brachytherapy in norway

Conditions: Prostate Cancer

Summary: there are 3 articles that will be written about the experience with hdr-brachytherapy (hdr-bt) in patients with high-risk prostate cancer in norway as part of a doctorial thesis-project. the project will focus on survival, side-effects and dosimetry variables as the main points of interest.

first article will compare overall and prostate cancer specific-mortality in patients who has received hdr-bt compared to patients who has received external beam radiation therapy only (ebrt). patients who have been treated with hdr-bt have been enrolled in an approved registry at oslo university hospital since 2004. the control group (ebrt only) data are from the lancet published hallmark study spcg-7 (scandinavian prostate cancer group). this is a case-control study. second article will focus on side-effects of hdr-bt compared to ebrt patients. patients included in the registry described above have been sent (and completed with a 72% answer rate) a questionnaire of the standard expanded prostate cancer index (epic-26) form. this will be compared to patients who already have answered the same questionnaire in a previously published study (approved by the norwegian ethical committee). the third article will investigate if there are any association between patients reporting severe adverse effects after hdr-bt and the patients dosimetry reports (i.e are there a larger dose to the urethra or rectum in these patients?)

Eligibility criteria:
inclusion criteria: * age, high-risk prostate cancer, general good health, anatomical favourable condition for brachytherapy exclusion criteria: * poor health, metastasis, t3b stage tumour, prostate specific antigen (psa) levels \> 75, biological age \> 75 years
bruxism and severity of temporomandibular dsyfunction

Conditions: Temporomandibular Dysfunction

Summary: the aim of the study was to investigate the effect of bruxism on temporomanbular joint functionality and dysfunction severity in individuals with temporomandibular dysfunction (tmd).

the study included 91 individuals aged 20-55 years with tmd. participants who volunteered to participate in the study signed the informed consent form and completed the descriptive data form including demographic characteristics. the presence of bruxism in individuals with tmd was questioned and the maximum mouth opening measurement was recorded. tmd severity was assessed by fonseca's anamnestic questionnaire (faq), pain severity was assessed by numeric pain scale (nps), and masticatory and tmj functioning was assessed by jaw functional limitation scale-20 (jfls-20). the evaluations of the participants were performed only once.

Eligibility criteria:
inclusion criteria: * aged between 20 and 55 years, * diagnosed with tmd, * volunteer to participate in the study exclusion criteria: * having a non-reduced disc problem, * surgical operation due to spine, abdomen and/or tmj problem, * trauma, cancer, neurological problems, congenital anomalies, musculoskeletal system problems, * systemic disease, * facial paralysis * less than 6 months of receiving any treatment related to the spine and tmj

Keywords: temporomandibular dysfunction bruxism chewing functionality
tranexamic acid to reduce contraceptive-related bleeding side effects

Conditions: Bleeding; Contraceptive Device; Complications

Summary: this randomized double blinded trial seeks to determine whether tranexamic acid (txa) is an efficacious treatment for contraceptive induced menstrual changes (cimc) including irregular, bothersome bleeding caused by the etonogestrel subdermal contraceptive implant (eng implant). participants will be randomized into the txa treatment arm or a placebo. they will begin taking the medication after three consecutive days of bleeding. participants will track their bleeding using an automated text message service


Eligibility criteria:
inclusion criteria: * english or spanish speaking * in good general health * have etonogestrel (eng) subdermal contraceptive implant (must be palpable to prove that an eng implant is in place at time of screening and enrollment) * experience frequent or prolonged bleeding while using eng implant (\>7 days of continuous bleeding/spotting in the last 30 days, or 2 or more episodes of bleeding/spotting in the last 30 days) * implant use for at least 30 days prior to screening visit * willing to continue using the implant for at least 30 days from study enrollment * access to a reliable cell phone and must be willing to receive and respond to a daily text or email message to assess bleeding and use of study drug * negative gonorrhea/chlamydia screening performed at screening visit exclusion criteria: * centers for disease control medical eligibility for contraceptive use category 3 or 4 for contraceptive usage * currently pregnant * less than 6 months postpartum, less than 6 weeks abortion, not breast/chest feeding (cessation of lactation at least 6 weeks prior to enrollment) * undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant * bleeding dyscrasia * anticoagulation use * active cervicitis * allergy to tranexamic acid * known renal insufficiency * history of venous thromboembolism * current or past breast or uterine malignancy * concurrent use of p450 pathway inducing drug * implant is due to be switched out in 2 months or less from enrollment * routine or chronic use of non-steroidal anti-inflammatory drugs (nsaids once daily or \>= 14 days per month) * currently using oral contraceptives in addition to implant (to be eligible, needs to have 4-6 week washout period) * prior pregnancy occurred while nexplanon/implanon was in place * chronic use of cannabidiol, thc, or marijuana (\>3 times per week) (patients could have used cannabidiol, thc, or marijuana chronically in the past, but must have a washout time period of no use for at least one month prior to the study) * chronic use of cigarettes (\>1 cigarette per week) (patients could have used cigarettes chronically in the past, but must have a washout time period of no use for at least six months prior to the study)

Keywords: tranexamic acid contraceptive implant
pf-06804103 dose escalation in her2 positive and negative (negative only in part 2) solid tumors

Conditions: Breast Neoplasms

Summary: the study will evaluate the safety, pharmacokinetics and pharmacodynamics of increasing doses of pf-06804103 in patients with her2 positive and negative breast and gastric cancer (her2 positive only and gastric were studied in part 1a only). the study will expand to look at selected doses in patients with her2 positive and negative breast cancer.


Eligibility criteria:
inclusion criteria: * her2 positive breast cancer or gastric cancer that is resistant to standard therapy or for which no standard therapy is available (part 1a only) * her2 positive and negative breast cancer (part 2a) * her2 negative breast cancer (part 1b \& part 2b) * performance status of 0 or 1 * adequate bone marrow, kidney and liver function exclusion criteria: * known cns disease including, but not limited to, metastases * history of exposure to certain cumulative doses of anthracyclines * grade 3 or higher hypersensitivity reaction to prior receipt of any antibody therapy * active and clinically significant bacterial, fungal, or viral infection * abnormal cardiac function defined by a lvef \<50% by echo or muga * patients with previous history or active interstitial lung disease or pulmonary fibrosis, or a history of other clinically significant lung diseases

Keywords: her2 pf-06804103 adc breast cancer neoplasms solid tumors human epidermal growth receptor 2
physiological effects of lactate in individuals with chronic heart failure

Conditions: Heart Failure, Systolic

Summary: background: lactate is continuously produced in the human body through two primary processes: glycolysis and microbial fermentation in the gastrointestinal tract. at rest, its concentration in the bloodstream typically ranges from 1 to 2 mmol/l. however, during periods of physical exertion or insufficient oxygen supply, such as during intense exercise, lactate levels significantly increase. traditionally, lactate was perceived as a byproduct of anaerobic metabolism. nevertheless, emerging research has illuminated its vital role as both a signaling molecule and a crucial energy source for vital organs like skeletal muscle, brain, and the heart. objectives: the primary aim of this study is to investigate the impact of physiological levels of circulating lactate on the hemodynamics of individuals with chronic heart failure. this research seeks to understand how lactate affects the cardiovascular response in this specific patient population. design and endpoints: the study design employs a double-blind, randomized crossover approach involving 12 heart failure patients. each participant will undergo two separate visits. visit 1: participants will receive a three-hour intravenous infusion of either a racemic (d/l) mixture of sodium lactate or an intravenous isotonic sodium chloride placebo, with a subsequent crossover to the opposite infusion on the same day. visit 2: similar to the first visit, participants will receive either an orally administered racemic (d/l) mixture of sodium lactate or an isocaloric, isovolumic oral placebo (maltodextrin), with a crossover to the opposite administration after three hours. the study's endpoints include cardiac output (primary), mixed venous saturation (svo2), pulmonary wedge pressure, resting echocardiography (left ventricular ejection fraction and myocardial work efficiency), and measurements of vasoactive substances in blood samples. methods: the study employs invasive swan-ganz monitoring to measure cardiac output, echocardiography, and frequent venous blood sample collections. these measurements and samples will be taken at specific intervals during the study visits. intervention: to investigate the isolated hemodynamic and physiological effects of lactate, the study utilizes lactate infusion and ingestion to induce a state of hyperlactatemia within the physiological range. the intended dosages aim to stay within the physiological range, with no values expected to exceed 3-4 mmol/l.


Eligibility criteria:
inclusion criteria: * chronic heart failure * nyha ii-iii * left ventricular ejection fraction \<40% * negative urine-hcg for women with childbearing potential exclusion criteria: * diabetes or hba1c \>48 mmol/mol * significant cardiac valve disease * severe stable angina pectoris * severe comorbidity as judged by the investigator * inability to give informed consent * age \<18 years * other disease or treatment making subject unsuitable for study participation as judged by the investigator.
impact of vitamin d supplementation on severity of pediatric atopic dermatitis

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to determine whether oral vitamin d supplementation improves the clinical severity of atopic dermatitis in children. in addition, this study plans to evaluate the effects of vitamin d supplementation on several key aspects of the immune system of children with atopic dermatitis.


Eligibility criteria:
inclusion criteria: * atopic dermatitis diagnosed according to hanifin and rajka criteria * age 2 - 17 years * scorad 10 - 103 exclusion criteria: * active skin infection * history of underlying illness causing immunosuppression within the past 2 years * immunosuppressors taken within the past month * parathyroid disease * sarcoidosis * acute or chronic renal disease * hyper or hypocalcemia * thyroid disease * osteomalacia or paget's disease of bone * malabsorption * use of vd supplements (\> 400 iu daily) or fish oil supplements in the past month * treatment for known vd deficiency in the last 6 months * treatment with moderate or high potency topical corticosteroids, oral or topical antibiotics, oral antivirals, immune enhancers, or topical calcineurin inhibitors in the past 7 days * phototherapy in the past month * autoimmune disease or immunodeficiency * planned trip to sunny climate during the 6-week study.

Keywords: atopic dermatitis vitamin d
evaluation for benign and malignant pulmonary ground-glass nodules based on mri dynamic contrast enhanced imaging

Conditions: Pulmonary Nodules

Summary: computed tomography (ct) is critical for the diagnosis of lung nodules as well as for therapeutic management. repeated ct examinations will raise the issue of the cumulative radiation dose and subsequent risk of cancer, thus pushing the need for imaging techniques using low or no radiation dose. magnetic resonance imagery (mri) with ultrashort echo time (ute) pulse sequences with high signal-to-noise and spatial resolution is a promising alternative for lung nodules imaging.the purpose of the study is to evaluate the value of dynamic contrast-enhanced mr imaging (dce-mri) to discriminate of malignant from benign lesions.

computed tomography (ct) is critical for the diagnosis of lung nodules as well as for therapeutic management. repeated ct examinations will raise the issue of the cumulative radiation dose and subsequent risk of cancer, thus pushing the need for imaging techniques using low or no radiation dose. magnetic resonance imagery (mri) with ultrashort echo time (ute) pulse sequences with high signal-to-noise and spatial resolution is a promising alternative for lung nodules imaging.the purpose of the study is to evaluate the value of dce-mri to discriminate of malignant from benign lesions.in this study, the investigators are going to validate the efficacy of the dce-mri for diagnosing early lung cancer by comparing results of the pre-surgery mri imaging with the post-surgery pathology.

Eligibility criteria:
inclusion criteria: * ground-glass pulmonary nodules found by ct scan * plan to accept surgery or puncture due to the pulmonary nodules * absence of treatment such as chemotherapy or radiotherapy and biopsy * adequate renal function to tolerate intravenous gadolinium * agree to sign informed consent * able to lie still during dce-mri exclusion criteria: * fail to understand or agree to sign informed consent * implanted pacemaker or cardiac defibrillator * contraindications to undergoing mri * uncontrolled intercurrent illness * pregnant or breastfeeding
time of permanence of dressing following breast reconstruction

Conditions: Surgical Site Infection

Summary: this randomized clinical trial was designed to assess the influence of time of dressing after breast reconstruction procedures on surgical site infections rates and skin colonization.

the rates of surgical site infections (ssi) after clean operations range from 1 to 2%. however, infection rates in the breast surgical literature tend to be higher, with reported rates ranging from 2 to 30%. in plastic surgery operations, to minimize the risk of ssi is imperative, since even minor infections are able to complicate the healing process and harm the cosmetic result. the centers for disease control and prevention has established guidelines for postoperative incision care. however, there is no recommendation to cover an incision closed primarily beyond 48 hours, nor on the appropriate time to shower or bathe with an uncovered incision. this remains an unresolved issue.

Eligibility criteria:
inclusion criteria: •candidate to immediate or delayed breast reconstruction after mastectomy or segmental mastectomy exclusion criteria: * use of antibiotics at the time of the operation * presence of skin lesions on the surgical site * body mass index over 35kg/m2 * hard smoking

Keywords: breast plastic surgery bandages surgical site infection skin colonization
implementation of telerehabilitation in support of home-based physical exercise for heart failure

Conditions: Heart Failure, Systolic; Heart Failure, Diastolic; Chronic Kidney Diseases; Cardiorenal Syndrome

Summary: itishope4hf is a randomized controlled trial of telerehabilitation in a heart failure population. the goal is to evaluate if a home-based telerehabilitation project can increase physical activity in heart failure patients. patients will be provided telerehabilitation or advice on physical activity (standard care).

outpatient cardiac rehabilitation programs are well documented as an important part of treatment and care for heart failure patients. training with instruction gives the participant a commitment to participate. the result is increased activity compared to controls. this trial will include participants from the about 75 % of heart failure patients who for some reason do not participate in regular outpatient rehabilitation. distance to rehabilitation centers and the psychological burden of a group setting are believed to be important reasons for not participating. telerehabilitation can hopefully overcome these hurdles for many patients, and thereby provide instructed training for these patients. the trial will also include patients with renal disease. heart disease is the main cause of death in patients with renal disease, even at younger ages. because of the complexity of both optimal medical treatment and fluid balance, these patients are often not included in clinical trials. the cardiorenal crosstalk will be explored, how in influence the heart failure phenotypes and the response to exercise.

Eligibility criteria:
inclusion criteria: * heart failure (hfpef or hfref) according to european guidelines. * moderate or severe signs and symptoms of heart failure (nyha ii-iii) in the 6 months prior to enrolment. * n-terminal pro brain natriuretic peptide (nt-probnp) \> 300 pmol/l. * stable (\> 4 weeks) medical therapy for risk factor control. * capability to provide signed, informed, written consent. exclusion criteria: * attendance at a rehabilitation program in the 6 months prior to enrolment. * non-heart failure causes of heart failure symptoms (significant valvular disease, coronary disease available for revascularization, uncontrolled hypertension, arrhythmia). * severe or very severe pulmonary disease (eg. copd gold iii-iv). * presence of conditions which might prevent patients from safely exercising at home.

Keywords: hfpef hfref cardiorenal syndrome exercise telerehabilitation rehabilitation